Advances in diffuse malignant peritoneal mesothelioma
- PDF / 2,132,979 Bytes
- 12 Pages / 618 x 808 pts Page_size
- 72 Downloads / 186 Views
Tristan D. Yan Raffit Hassan Laura Welch Paul H. Sugarbaker
Received: 23 March 2007 Accepted in revised form: 30 March 2007
P.H. Sugarbaker (쾷) Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington Hospital Center, 106 Irving Street, NW, Suite 3900, Washington, DC, USA 20010 Tel.: +1-202-877-3908 Fax: +1-202-877-8602 e-mail: [email protected] P.H. Sugarbaker • T.D. Yan Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington Hospital Center, Washington, DC, USA R. Hassan Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institute of Health Bethesda, MD, USA L. Welch Center to Protect Worker’s Rights, Silver Spring, MD, USA
REVIEW
Advances in diffuse malignant peritoneal mesothelioma
Abstract Malignant mesothelioma is a highly aggressive neoplasm. The incidence of malignant mesothelioma is increasing worldwide. Diffuse malignant peritoneal mesothelioma (DMPM) represents one-fourth of all mesotheliomas. Association of asbestos exposure with DMPM has been observed, especially in males. A great majority of patients present with abdominal pain and distension, caused by accumulation of tumors and ascitic fluid. In the past, DMPM was considered a pre-terminal condition; therefore attracted little attention. Patients invariably died from their disease within a year. Recently, several prospective trials have demonstrated median survival of 40 to 90 months and 5-year survival of 30% to 60% after the combined treatment using cytoreductive surgery and perioperative intraperitoneal chemotherapy. This improvement in survival has
Introduction Malignant mesothelioma is a highly aggressive primary neoplasm of the serosal lining of the pleura, peritoneum, pericardium, or tunica vaginalis [1]. The incidence of malignant mesothelioma is increasing worldwide. Probably due to the because of extensive use of asbestos in building materials in the past. It is not expected to peak for another 5 to 20 years [2]. Diffuse malignant peritoneal mesothelioma (DMPM) is the second most common type of mesothelioma [1]. Patients who suffer from this disease usually present
prompted new searches into the medical science related to DMPM, a disease previously ignored as uninteresting. This review article focuses on the key advances in the epidemiology, diagnosis, staging, treatments and prognosis of DMPM that have occurred in the past decade.
Key words Peritoneal mesothelioma • Asbestos • Cytoreductive surgery • Peritonectomy • Intraperitoneal chemotherapy • Mesothelin • Doxorubicin • Cisplatin • Pemetrexed
with abdominal pain or distension. As the disease progresses, they invariably die from intestinal obstruction or terminal starvation within a year. Due to the infrequent occurrence and the lack of understanding of the natural history of DMPM, traditionally there seemed to be a mutual agreement among medical practitioners that patients with this condition were preterminal. Since the disease was first described by Miller and Wynn in 1908 few t
Data Loading...
